{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T03:29:21Z","timestamp":1775791761770,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100021471","name":"Women and Gender Equality Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021471","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024972","name":"Health Education and Training Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008102","name":"University of Cincinnati","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014489","name":"Johnson and Johnson Pharmaceutical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014489","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019153","name":"Harrison McCain Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019153","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015138","name":"J. Willard and Alice S. Marriott Foundation","doi-asserted-by":"publisher","award":["6,323,236 B2"],"award-info":[{"award-number":["6,323,236 B2"]}],"id":[{"id":"10.13039\/100015138","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatric Clinics of North America"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.psc.2025.08.014","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:53:51Z","timestamp":1758765231000},"page":"203-216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Innovative Pharmacological Approaches to Eating Disorder Treatment"],"prefix":"10.1016","volume":"49","author":[{"given":"Aaron","family":"Keshen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Touyz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillipa","family":"Hay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan L.","family":"McElroy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.psc.2025.08.014_bib1","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1001\/archgenpsychiatry.2011.74","article-title":"Mortality rates in patients with anorexia nervosa and other eating disorders. A meta-analysis of 36 studies","volume":"68","author":"Arcelus","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.psc.2025.08.014_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104857","article-title":"Treatment of eating disorders: a systematic meta-review of meta-analyses and network meta-analyses","volume":"142","author":"Monteleone","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"issue":"2","key":"10.1016\/j.psc.2025.08.014_bib3","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4088\/JCP.15m10393","article-title":"Recovery from anorexia nervosa and bulimia nervosa at 22-Year Follow-Up","volume":"78","author":"Eddy","year":"2017","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.psc.2025.08.014_bib4","series-title":"Handbook of eating disorders and obesity","first-page":"349","article-title":"Pharmacotherapy of eating disorders","author":"Herpterz","year":"2024"},{"issue":"1","key":"10.1016\/j.psc.2025.08.014_bib5","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s40337-024-01111-y","article-title":"Beyond the numbers: reimagining healing with psychedelics for eating disorders","volume":"12","author":"Lafrance","year":"2024","journal-title":"J Eat Disord"},{"issue":"1","key":"10.1016\/j.psc.2025.08.014_bib6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s40337-024-01125-6","article-title":"Psychedelics and the treatment of eating disorders: considerations for future research and practice","volume":"12","author":"Lacroix","year":"2024","journal-title":"J Eat Disord"},{"issue":"1","key":"10.1016\/j.psc.2025.08.014_bib7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s40337-023-00944-3","article-title":"What kind of illness is anorexia nervosa? Revisited: some preliminary thoughts to finding a cure","volume":"11","author":"Touyz","year":"2023","journal-title":"J Eat Disord"},{"issue":"1","key":"10.1016\/j.psc.2025.08.014_bib8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40337-022-00538-5","article-title":"The future of eating disorders research: an editorial","volume":"10","author":"Touyz","year":"2022","journal-title":"J Eat Disord"},{"issue":"3","key":"10.1016\/j.psc.2025.08.014_bib9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/2045125316638008","article-title":"Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years","volume":"6","author":"Dos Santos","year":"2016","journal-title":"Ther Adv Psychopharmacol"},{"issue":"1","key":"10.1016\/j.psc.2025.08.014_bib10","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s40337-024-01185-8","article-title":"Exploring the neurobiological correlates of psilocybin-assisted psychotherapy in eating disorders: a review of potential methodologies and implications for the psychedelic study design","volume":"12","author":"Koning","year":"2024","journal-title":"J Eat Disord"},{"issue":"8","key":"10.1016\/j.psc.2025.08.014_bib11","first-page":"777","article-title":"Psilocybin in the treatment of anorexia nervosa: the English transition of a French 1959 case study","volume":"179","author":"Verroust","year":"2021","journal-title":"Ann Med-Psychol Rev Psychiatr"},{"issue":"8","key":"10.1016\/j.psc.2025.08.014_bib12","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1038\/s41591-023-02455-9","article-title":"Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study","volume":"29","author":"Peck","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.psc.2025.08.014_bib15","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40519-020-01000-8","article-title":"Positive effects of psychedelics on depression and wellbeing scores in individuals reporting an eating disorder","volume":"26","author":"Spriggs","year":"2021","journal-title":"Eat Weight Disord"},{"key":"10.1016\/j.psc.2025.08.014_bib16","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jpsychires.2022.03.008","article-title":"MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD","volume":"149","author":"Brewerton","year":"2022","journal-title":"J Psychiatr Res"},{"issue":"1","key":"10.1016\/j.psc.2025.08.014_bib17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40337-022-00588-9","article-title":"A case series of group-based ketamine-assisted psychotherapy for patients in residential treatment for eating disorders with comorbid depression and anxiety disorders","volume":"10","author":"Robison","year":"2022","journal-title":"J Eat Disord"},{"issue":"5","key":"10.1016\/j.psc.2025.08.014_bib18","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/02791072.2017.1361559","article-title":"Nourishing the spirit: exploratory research on ayahuasca experiences along the continuum of recovery from eating disorders","volume":"49","author":"Lafrance","year":"2017","journal-title":"J Psychoact Drugs"},{"key":"10.1016\/j.psc.2025.08.014_bib19","article-title":"Psilocybin-assisted psychotherapy as a potential treatment for eating disorders: a narrative review of preliminary evidence","volume":"46","author":"Koning","year":"2024","journal-title":"Trends Psychiatry Psychother"},{"issue":"S1","key":"10.1016\/j.psc.2025.08.014_bib21","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1556\/2054.2023.00267","article-title":"Altered stakes: identifying gaps in the informed consent process for psychedelic-assisted therapy trials","volume":"7","author":"Harrison","year":"2023","journal-title":"J Psychedelic Studies"},{"issue":"14","key":"10.1016\/j.psc.2025.08.014_bib22","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.3390\/ijerph20146325","article-title":"Current discoveries and future implications of eating disorders","volume":"20","author":"Feng","year":"2023","journal-title":"Int J Environ Res Publ Health"},{"key":"10.1016\/j.psc.2025.08.014_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2022.887255","article-title":"Psychedelic-assisted psychotherapy-a systematic review of associated psychological interventions","volume":"13","author":"Cavarra","year":"2022","journal-title":"Front Psychol"},{"key":"10.1016\/j.psc.2025.08.014_bib24","author":"Fairburn"},{"issue":"6","key":"10.1016\/j.psc.2025.08.014_bib25","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1002\/eat.24198","article-title":"Adaptive design trials in eating disorder research: a scoping review","volume":"57","author":"Edney","year":"2024","journal-title":"Int J Eat Disord"},{"issue":"1","key":"10.1016\/j.psc.2025.08.014_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005278","article-title":"Ten simple rules to enable multi-site collaborations through data sharing","volume":"13","author":"Boland","year":"2017","journal-title":"PLoS Comput Biol"},{"issue":"1","key":"10.1016\/j.psc.2025.08.014_bib27","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1556\/2054.2019.015","article-title":"The psychedelic renaissance and the limitations of a White-dominant medical framework: a call for indigenous and ethnic minority inclusion","volume":"4","author":"George","year":"2019","journal-title":"J Psychedelic Stud"},{"issue":"5","key":"10.1016\/j.psc.2025.08.014_bib28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40261-015-0354-y","article-title":"Lisdexamfetamine dimesylate: prodrug delivery, amphetamine exposure and duration of efficacy","volume":"36","author":"Ermer","year":"2016","journal-title":"Clin Drug Invest"},{"issue":"3","key":"10.1016\/j.psc.2025.08.014_bib29","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jamapsychiatry.2014.2162","article-title":"Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial","volume":"72","author":"McElroy","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1016\/j.psc.2025.08.014_bib30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1176\/appi.ajp.20230982","article-title":"Cognitive behavioral therapy and lisdexamfetamine, alone and combined, for binge-eating disorder with obesity: a randomized controlled trial","volume":"182","author":"Grilo","year":"2024","journal-title":"Am J Psychiatry"},{"issue":"12","key":"10.1016\/j.psc.2025.08.014_bib31","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1017\/S003329172400148X","article-title":"Lisdexamfetamine maintenance treatment for binge-eating disorder following successful treatments: randomized double-blind placebo-controlled trial","volume":"54","author":"Grilo","year":"2024","journal-title":"Psychol Med"},{"issue":"17","key":"10.1016\/j.psc.2025.08.014_bib32","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1080\/14656566.2024.2428371","article-title":"Can we effectively manage binge eating disorder with pharmacotherapy?","volume":"25","author":"Hay","year":"2024","journal-title":"Expet Opin Pharmacother"},{"issue":"3","key":"10.1016\/j.psc.2025.08.014_bib33","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/eat.23650","article-title":"The potential role of stimulants in treating eating disorders","volume":"55","author":"Keshen","year":"2022","journal-title":"Int J Eat Disord"},{"issue":"5","key":"10.1016\/j.psc.2025.08.014_bib34","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/eat.23480","article-title":"A feasibility study evaluating lisdexamfetamine dimesylate for the treatment of adults with bulimia nervosa","volume":"54","author":"Keshen","year":"2021","journal-title":"Int J Eat Disord"},{"issue":"2","key":"10.1016\/j.psc.2025.08.014_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2498","article-title":"Effectiveness of olanzapine in the treatment of anorexia nervosa: a systematic review and meta-analysis","volume":"12","author":"Han","year":"2022","journal-title":"Brain Behav"},{"issue":"10","key":"10.1016\/j.psc.2025.08.014_bib36","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1089\/cap.2017.0133","article-title":"Adjunctive use of olanzapine in the treatment of avoidant restrictive food intake disorder in children and adolescents in an eating disorders program","volume":"27","author":"Brewerton","year":"2017","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"8","key":"10.1016\/j.psc.2025.08.014_bib37","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1089\/cap.2015.0145","article-title":"Mirtazapine for choking phobia: report of a pediatric case","volume":"25","author":"Tan\u0131d\u0131r","year":"2015","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"Suppl 3","key":"10.1016\/j.psc.2025.08.014_bib38","first-page":"421","article-title":"Management of ARFID (avoidant restrictive food intake disorder) in a 12-year-old on a paediatric ward in a general hospital: use of mirtazapine, partial hospitalisation model and family based therapy","volume":"31","author":"Naviaux","year":"2019","journal-title":"Psychiatr Danub"},{"issue":"2","key":"10.1016\/j.psc.2025.08.014_bib39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/MJT.0000000000001338","article-title":"Mirtazapine improved eating patterns in avoidant\/restrictive food intake disorder","volume":"30","author":"Naguy","year":"2023","journal-title":"Am J Therapeut"},{"issue":"4","key":"10.1016\/j.psc.2025.08.014_bib40","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jaac.2018.01.011","article-title":"Mirtazapine and weight gain in avoidant and restrictive food intake disorder","volume":"57","author":"Gray","year":"2018","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.psc.2025.08.014_bib41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40337-018-0205-3","article-title":"Treatment of children and adolescents with avoidant\/restrictive food intake disorder: a case series examining the feasibility of family therapy and adjunctive treatments","volume":"6","author":"Spettigue","year":"2018","journal-title":"J Eat Disord"},{"issue":"2","key":"10.1016\/j.psc.2025.08.014_bib42","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/1359104520981401","article-title":"Multimodal therapy for rigid, persistent avoidant\/restrictive food intake disorder (ARFID) since infancy: a case report","volume":"26","author":"Dolman","year":"2021","journal-title":"Clin Child Psychol Psychiatr"},{"issue":"2","key":"10.1016\/j.psc.2025.08.014_bib43","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1089\/cap.2021.0038","article-title":"Selective serotonin reuptake inhibitors and hydroxyzine in the treatment of avoidant\/restrictive food intake disorder in children and adolescents: rationale and evidence","volume":"32","author":"Mahr","year":"2022","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"6","key":"10.1016\/j.psc.2025.08.014_bib44","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1089\/cap.2018.0005","article-title":"Buspirone treatment of anxiety in an adolescent female with avoidant\/restrictive food intake disorder","volume":"28","author":"Okereke","year":"2018","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"6","key":"10.1016\/j.psc.2025.08.014_bib45","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2017.126","article-title":"Successful pharmacotherapy for the treatment of severe feeding aversion with mechanistic insights from cross-species neuronal remodeling","volume":"7","author":"Sharp","year":"2017","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.psc.2025.08.014_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.112961","article-title":"Avoidant\/restrictive food intake disorder: a systematic scoping review of the current literature","volume":"288","author":"Bourne","year":"2020","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.psc.2025.08.014_bib47","first-page":"13","article-title":"Treatment of avoidant\/restrictive food intake disorder: a systematic review","volume":"4","author":"Dalle","year":"2020","journal-title":"Int J Eat Disord"},{"issue":"8","key":"10.1016\/j.psc.2025.08.014_bib48","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/15622975.2023.2179663","article-title":"World Federation of societies of biological psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders","volume":"24","author":"Himmerich","year":"2023","journal-title":"World J Biol Psychiatr"},{"issue":"4","key":"10.1016\/j.psc.2025.08.014_bib49","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/WNF.0000000000000160","article-title":"Donepezil as add-on treatment for resistant obsessive-compulsive disorder: retrospective case series","volume":"39","author":"Bergman","year":"2016","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"10.1016\/j.psc.2025.08.014_bib52","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s40337-023-00796-x","article-title":"Secondary outcomes and qualitative findings of an open-label feasibility trial of lisdexamfetamine dimesylate for adults with bulimia nervosa","volume":"11","author":"Dixon","year":"2023","journal-title":"J Eat Disord"},{"issue":"5","key":"10.1016\/j.psc.2025.08.014_bib54","doi-asserted-by":"crossref","first-page":"19m13068","DOI":"10.4088\/JCP.19m13068","article-title":"Efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, placebo-controlled, flexible-dose clinical trial","volume":"81","author":"McElroy","year":"2020","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.psc.2025.08.014_bib55","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1017\/S1092852920001406","article-title":"Efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, placebo-controlled, fixed-dose clinical trial","volume":"26","author":"Grilo","year":"2021","journal-title":"CNS Spectr"},{"key":"10.1016\/j.psc.2025.08.014_bib57","unstructured":"Solriamfetol in Binge Eating Disorder. Clinicaltrials.gov identifier: NCT04602936. Last updated March 8, 2023. Accessed January 21, 2025."},{"key":"10.1016\/j.psc.2025.08.014_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106587","article-title":"Study protocol and rationale for a randomized, placebo-controlled trial of solriamfetol to treat binge eating disorder","volume":"110","author":"Guerdjikova","year":"2021","journal-title":"Contemp Clin Trials"},{"issue":"3","key":"10.1016\/j.psc.2025.08.014_bib60","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.orcp.2015.03.005","article-title":"Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide - a pilot study","volume":"9","author":"Robert","year":"2015","journal-title":"Obes Res Clin Pract"},{"issue":"2","key":"10.1016\/j.psc.2025.08.014_bib61","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/osp4.619","article-title":"A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder","volume":"9","author":"Allison","year":"2022","journal-title":"Obes Sci Pract"},{"issue":"2","key":"10.1016\/j.psc.2025.08.014_bib62","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/JCP.0000000000001803","article-title":"Liraglutide in obese or overweight individuals with stable bipolar disorder","volume":"44","author":"McElroy","year":"2024","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.psc.2025.08.014_bib63","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/eat.24109","article-title":"Use of glucagon-like peptide-1 receptor agonists in eating disorder populations","volume":"57","author":"Bartel","year":"2024","journal-title":"Int J Eat Disord"},{"issue":"2","key":"10.1016\/j.psc.2025.08.014_bib64","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/JCP.0000000000001820","article-title":"Semaglutide misuse in atypical anorexia Nervosa-A case report","volume":"44","author":"Guerdjikova","year":"2024","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.psc.2025.08.014_bib65","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/eat.23192","article-title":"A randomized, placebo-controlled crossover trial of phentermine-topiramate ER in patients with binge-eating disorder and bulimia nervosa","volume":"53","author":"Safer","year":"2020","journal-title":"Int J Eat Disord"},{"issue":"11","key":"10.1016\/j.psc.2025.08.014_bib66","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1002\/oby.23898","article-title":"Naltrexone\/bupropion for binge-eating disorder: a randomized, double-blind, placebo-controlled trial","volume":"31","author":"Grilo","year":"2023","journal-title":"Obesity"},{"issue":"3","key":"10.1016\/j.psc.2025.08.014_bib69","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/eat.22114","article-title":"A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder","volume":"46","author":"McElroy","year":"2013","journal-title":"Int J Eat Disord"},{"issue":"11","key":"10.1016\/j.psc.2025.08.014_bib70","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/eat.24039","article-title":"Efficacy, safety, and tolerability of nivasorexant in adults with binge-eating disorder: a randomized, phase II proof of concept trial","volume":"56","author":"McElroy","year":"2023","journal-title":"Int J Eat Disord"}],"container-title":["Psychiatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X2500084X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X2500084X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T02:26:17Z","timestamp":1775787977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0193953X2500084X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0193953X2500084X"],"URL":"https:\/\/doi.org\/10.1016\/j.psc.2025.08.014","relation":{},"ISSN":["0193-953X"],"issn-type":[{"value":"0193-953X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovative Pharmacological Approaches to Eating Disorder Treatment","name":"articletitle","label":"Article Title"},{"value":"Psychiatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psc.2025.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}